ReviewDegenerative neurological and neuromuscular disease2012

Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy.

Joel N BuxbaumPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.